Family Medicine Doctors in Somerdale, NJ Accepting Medicare

3 Family Medicine doctors found. Showing 1 - 3

Dr. Desmond Cheng, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Somerdale Sq, Somerdale, NJ 08083 Phone: 856-309-7700    Fax: 856-566-8944

Dr. Raleke O Adibe, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 S White Horse Pike, Somerdale, NJ 08083 Phone: 856-545-9620

Dr. Christopher J Barone, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Somerdale Sq, Somerdale, NJ 08083 Phone: 856-309-7700    Fax: 856-661-5162

News Archive

Antisocial behavior in children associated with gene variant and environmental risk factors

For children with attention deficit hyperactivity disorder (ADHD), possessing a variant of a gene involved in brain signaling may predict antisocial behavior and increase susceptibility to the effects of lower birth weight, according to a study in the November issue of Archives of General Psychiatry.

Democratic candidates spend more on ads against than for health reform

Politico: Democratic candidates are spending three times more — nearly $1 million — in advertising against health reform than for it. "Since the beginning of Congress's August recess, Democratic candidates have poured $930,000 into ads deriding the health overhaul but just $300,000 in pro-reform spots, according to Evan Tracey at Kantar Media."

Topline results from Alkermes' ALKS 37 phase 2b study on opioid-induced constipation

Alkermes plc today announced topline results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation. The multicenter, randomized, double-blind, placebo-controlled, repeat-dose study was designed to assess the safety, tolerability, pharmacokinetic profile and efficacy of ALKS 37 in approximately 150 patients.

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

Read more Medical News

› Verified 5 days ago